BR0015419A - Complexo contendo ácido nucleico, composição farmacêutica, e , métodos para controlar uma taxa de liberação de ácido nucleico, e para aumentar a função de um ácido nucleico, célula fagocìtica, e, métodos para exibir uma função de um ácido nucleico em um sìtio alvo, e para tratar uma doença ou distúrbio - Google Patents
Complexo contendo ácido nucleico, composição farmacêutica, e , métodos para controlar uma taxa de liberação de ácido nucleico, e para aumentar a função de um ácido nucleico, célula fagocìtica, e, métodos para exibir uma função de um ácido nucleico em um sìtio alvo, e para tratar uma doença ou distúrbioInfo
- Publication number
- BR0015419A BR0015419A BR0015419-9A BR0015419A BR0015419A BR 0015419 A BR0015419 A BR 0015419A BR 0015419 A BR0015419 A BR 0015419A BR 0015419 A BR0015419 A BR 0015419A
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- function
- complex
- methods
- target site
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
"COMPLEXO CONTENDO áCIDO NUCLEICO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA CONTROLAR UMA TAXA DE LIBERAçãO DE áCIDO NUCLEICO, E PARA AUMENTAR A FUNçãO DE UM áCIDO NUCLEICO CéLULA FAGOCìTICA E, MéTODOS PARA EXIBIR UMA FUNçãO DE UM áCIDO NUCLEICO EM UM SìTIO ALVO E PARA TRATAR UMA DOENçA OU DISTúRBIO". é descrito um complexo contendo ácido nucleico, contendo um ácido nucleico e um polímero biodegradável, especialmente um polímero biodegradável insolúvel em água positivamente carregado. O complexo tem as excelentes propriedades de sustentavelmente liberar um ácido nucleico, especialmente DNA, para um sítio em necessidade de tratamento. Uma vez que o complexo pode ser acomodado em fagócitos tais como macrófagos e distribuído especificamente para o sítio alvo, a função do ácido nucleico pode ser exibida em uma maneira específica de sítio alvo e, assim, terapia de gene mais específica pode ser conseguida. O complexo não tem efeitos adversos, tais como ocorrência de recombinantes ou toxicidade, que poderia ser causada pela utilização de um vetor de vírus, tal como adenovírus, ou lipossoma. Assim, o complexo é particularmente preferível para o campo da terapia de gene. Além disso, o complexo aumenta o efeito biológico do ácido nucleico introduzido dentro das células, permitindo uma terapia de gene com uma mais baixa dose de ácidos nucleicos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31818799 | 1999-11-09 | ||
JP2000278878A JP2001199903A (ja) | 1999-11-09 | 2000-09-13 | 核酸含有複合体 |
PCT/JP2000/007882 WO2001034206A2 (en) | 1999-11-09 | 2000-11-09 | Nucleic acid-containing complex |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0015419A true BR0015419A (pt) | 2002-07-02 |
Family
ID=26569281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0015419-9A BR0015419A (pt) | 1999-11-09 | 2000-11-09 | Complexo contendo ácido nucleico, composição farmacêutica, e , métodos para controlar uma taxa de liberação de ácido nucleico, e para aumentar a função de um ácido nucleico, célula fagocìtica, e, métodos para exibir uma função de um ácido nucleico em um sìtio alvo, e para tratar uma doença ou distúrbio |
Country Status (11)
Country | Link |
---|---|
US (2) | US7276594B1 (pt) |
EP (1) | EP1229941A2 (pt) |
JP (1) | JP2001199903A (pt) |
KR (1) | KR100873593B1 (pt) |
CN (1) | CN100417418C (pt) |
AU (1) | AU1303401A (pt) |
BR (1) | BR0015419A (pt) |
CA (1) | CA2389506A1 (pt) |
IL (2) | IL149491A0 (pt) |
TW (1) | TWI267380B (pt) |
WO (1) | WO2001034206A2 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001199903A (ja) * | 1999-11-09 | 2001-07-24 | Eizo Mori | 核酸含有複合体 |
JP2003516365A (ja) * | 1999-12-08 | 2003-05-13 | フアルマコンセプツ・エイビー | 核酸送達系 |
DE60134021D1 (de) * | 2000-06-27 | 2008-06-26 | Anges Mg Inc | Pharmazeutische zubereitungen zur angiogenese-therapie |
US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
EP1347776A2 (en) * | 2001-01-05 | 2003-10-01 | Intercell Biomedizinische Forschungs- und Entwicklungs AG | Anti-inflammatory use of polycationic compounds |
JP2008067717A (ja) * | 2001-06-20 | 2008-03-27 | Dainippon Sumitomo Pharma Co Ltd | 核酸導入を促進させる方法 |
EP1407787B1 (en) | 2001-06-20 | 2009-04-29 | Dainippon Sumitomo Pharma Co., Ltd. | Method of promoting nucleic acid transfer |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
JP4022614B2 (ja) * | 2002-03-25 | 2007-12-19 | 国立大学法人大阪大学 | 新規なバイオビーズの作製方法 |
AU2003264507A1 (en) * | 2002-09-20 | 2004-04-08 | Koken Co., Ltd. | Site-specific gene conversion promoter and gene therapeutic |
KR100514092B1 (ko) * | 2002-11-23 | 2005-09-13 | 한국생명공학연구원 | 양이온성 고분자 물질과 음이온성 고분자 물질을 이용한 새로운 다중 유전자 전달 복합체 |
MXPA05006193A (es) * | 2002-12-11 | 2005-12-05 | Ferrosan As | Materiales basados en gelatina como hisopos. |
JPWO2004078213A1 (ja) * | 2003-03-06 | 2006-06-08 | 千佳子 錦織 | 対象物質導入用組成物及び対象物質導入方法 |
MXPA05013983A (es) * | 2003-06-30 | 2006-03-02 | Canji Inc | Encapsulacion polimerica de adenovirus. |
WO2005094894A1 (ja) * | 2004-03-31 | 2005-10-13 | Medgel Corporation | 細胞に核酸を導入するための製剤 |
JP4767195B2 (ja) * | 2004-08-27 | 2011-09-07 | ネオケミア株式会社 | 核酸皮膚外用製剤 |
JP2007182407A (ja) * | 2006-01-10 | 2007-07-19 | Medgel Corp | 徐放性ハイドロゲル製剤 |
CN1936011B (zh) * | 2006-10-17 | 2011-12-07 | 浙江医药高等专科学校 | 聚阳离子脂质体端粒酶反义寡核苷酸复合物及制备 |
CN102014973A (zh) | 2008-02-29 | 2011-04-13 | 弗罗桑医疗设备公司 | 用于促进止血和/或伤口愈合的装置 |
JP2009227641A (ja) * | 2008-03-25 | 2009-10-08 | Takahiko Saito | ステント |
WO2012129767A1 (zh) * | 2011-03-28 | 2012-10-04 | 南京大学 | 阳离子修饰的琼脂糖水凝胶和核酸药物组合物及制法和应用 |
EP2822474B1 (en) | 2012-03-06 | 2018-05-02 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
BR112014030962A2 (pt) | 2012-06-12 | 2017-06-27 | Ferrosan Medical Devices As | métodos para preparação e para reconstituição de uma composição seca adequada para uso em hemostase e cicatrização de feridas, e, kit hemostático |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
EP3470094B1 (en) | 2013-12-11 | 2020-07-22 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
WO2016058612A1 (en) | 2014-10-13 | 2016-04-21 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
WO2016102446A1 (en) | 2014-12-24 | 2016-06-30 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
EP3265112A4 (en) * | 2015-01-19 | 2018-10-03 | Rappaport Family Institute For Research In The Medical Sciences | Ubiquitin ligase kpc1 promotes processing of p105 nf-kappab1 to p50, eliciting strong tumor suppression |
WO2017005590A1 (en) | 2015-07-03 | 2017-01-12 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
WO2017019568A1 (en) * | 2015-07-24 | 2017-02-02 | Fibralign Corporation | Composition for targeted delivery of nucleic acid-based therapeutics |
WO2018186531A1 (ko) * | 2017-04-03 | 2018-10-11 | 선진뷰티사이언스(주) | 액적 방출 화장료 |
EP4321182A2 (en) | 2018-05-09 | 2024-02-14 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
CN111620985B (zh) * | 2019-02-28 | 2023-08-08 | 康码(上海)生物科技有限公司 | 共价固定dna的水凝胶及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294249A (en) * | 1987-03-27 | 1994-03-15 | Luisi Pier L | Blendpolymers |
US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
AU2946295A (en) * | 1994-06-27 | 1996-01-19 | Johns Hopkins University, The | Targeted gene delivery system |
WO1996000079A1 (en) * | 1994-06-27 | 1996-01-04 | The General Hospital Corporation | Graft co-polymer adducts of platinum (ii) compounds |
US5972707A (en) * | 1994-06-27 | 1999-10-26 | The Johns Hopkins University | Gene delivery system |
US6565842B1 (en) * | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
US6184037B1 (en) * | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
JP2001199903A (ja) * | 1999-11-09 | 2001-07-24 | Eizo Mori | 核酸含有複合体 |
-
2000
- 2000-09-13 JP JP2000278878A patent/JP2001199903A/ja active Pending
- 2000-11-08 TW TW089123586A patent/TWI267380B/zh not_active IP Right Cessation
- 2000-11-09 CN CNB008154775A patent/CN100417418C/zh not_active Expired - Fee Related
- 2000-11-09 IL IL14949100A patent/IL149491A0/xx active IP Right Grant
- 2000-11-09 US US10/129,906 patent/US7276594B1/en not_active Expired - Fee Related
- 2000-11-09 WO PCT/JP2000/007882 patent/WO2001034206A2/en active Application Filing
- 2000-11-09 EP EP00974862A patent/EP1229941A2/en not_active Withdrawn
- 2000-11-09 CA CA002389506A patent/CA2389506A1/en not_active Abandoned
- 2000-11-09 AU AU13034/01A patent/AU1303401A/en not_active Abandoned
- 2000-11-09 BR BR0015419-9A patent/BR0015419A/pt not_active Application Discontinuation
- 2000-11-09 KR KR1020027006003A patent/KR100873593B1/ko not_active IP Right Cessation
-
2002
- 2002-05-06 IL IL149491A patent/IL149491A/en not_active IP Right Cessation
-
2007
- 2007-04-25 US US11/740,200 patent/US20090203768A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001034206A8 (en) | 2001-07-26 |
CN100417418C (zh) | 2008-09-10 |
KR100873593B1 (ko) | 2008-12-11 |
US20090203768A1 (en) | 2009-08-13 |
EP1229941A2 (en) | 2002-08-14 |
CN1390141A (zh) | 2003-01-08 |
US7276594B1 (en) | 2007-10-02 |
WO2001034206A3 (en) | 2002-02-07 |
IL149491A (en) | 2008-04-13 |
CA2389506A1 (en) | 2001-05-17 |
AU1303401A (en) | 2001-06-06 |
JP2001199903A (ja) | 2001-07-24 |
IL149491A0 (en) | 2002-11-10 |
WO2001034206A2 (en) | 2001-05-17 |
KR20020060733A (ko) | 2002-07-18 |
TWI267380B (en) | 2006-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0015419A (pt) | Complexo contendo ácido nucleico, composição farmacêutica, e , métodos para controlar uma taxa de liberação de ácido nucleico, e para aumentar a função de um ácido nucleico, célula fagocìtica, e, métodos para exibir uma função de um ácido nucleico em um sìtio alvo, e para tratar uma doença ou distúrbio | |
Lopez-Bertoni et al. | Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival | |
Cai et al. | A hyaluronic acid-based hydrogel enabling CD44-mediated chondrocyte binding and gapmer oligonucleotide release for modulation of gene expression in osteoarthritis | |
Stępkowski et al. | Silver nanoparticles induced changes in the expression of NF-κB related genes are cell type specific and related to the basal activity of NF-κB | |
Nör et al. | The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells | |
IL173684A0 (en) | Disodium-4,4'-azo-bis-salicylate and pharmaceutical compositions containing the same | |
Wofford et al. | Biomaterial-mediated reprogramming of monocytes via microparticle phagocytosis for sustained modulation of macrophage phenotype | |
BR112013006088A2 (pt) | Construto de entrega isolado, e, composição farmacêuticapolinucleotídeo que encodifica um construtor de entrega, vetor de expressão, e célula hospedeira isolada" | |
Bucay | The biological significance of cancer: Mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment | |
Dai et al. | Key indexes and the emerging tool for tumor microenvironment editing | |
Uhmann et al. | Calcitriol inhibits hedgehog signaling and induces vitamin d receptor signaling and differentiation in the patched mouse model of embryonal rhabdomyosarcoma | |
Hou et al. | A combination of LightOn gene expression system and tumor microenvironment-responsive nanoparticle delivery system for targeted breast cancer therapy | |
Trivillin et al. | Radiobiology of BNCT mediated by GB-10 and GB-10+ BPA in experimental oral cancer | |
Liu et al. | “Domino” cascade reactor based on DNA hydrogel for synergistic treatment of malignant tumor | |
Mody | Introduction to polymeric drug delivery | |
Fife et al. | Endothelial cell transfection with cationic liposomes and herpes simplex-thymidine kinase mediated killing | |
Zhuang et al. | Genotoxicity associated with NO production in macrophages and co-cultured target cells | |
Yan et al. | pH-sensitive CuS@ Cu2S@ Au nanoparticles as a drug delivery system for the chemotherapy against colon cancer | |
Wu et al. | Targeting anion exchange of osteoclast, a new strategy for preventing wear particles induced-osteolysis | |
CN105311636B (zh) | 一种抗疱疹病毒软膏剂及其制备方法 | |
Hyoudou et al. | Cationized catalase-loaded hydrogel for growth inhibition of peritoneally disseminated tumor cells | |
Adiyat et al. | Intravesical chemotherapy | |
Huang et al. | Application and prospect of CRISPR/Cas9 technology in reversing drug resistance of non-small cell lung cancer | |
O'Connor et al. | Targeting epigenetic operations with HDAC inhibitor and hypomethylating drugs in combination exhibit synergy in preclinical and clinical experiences in drug resistant T-cell lymphoma (TCL): a translational focus on doublet development | |
Silvia et al. | STAT3 targeting by an aptamer-based conjugate for glioblastoma multiforme therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/64 (2017.01) |